Neelima KC holds a PhD in Bioengineering from Imperial College London, specialising in microfluidic technologies for cellular immunotherapy analysis. Before her PhD, she gained experience in the pharmaceutical industry in Boston and at Harvard Medical School, focusing on advanced scientific research and technology development.

Neelima spearheaded the development and optimisation of the microfluidic platform that underpins Avigen’s services. As a co-author of the platform’s foundational publication, she has been instrumental in scaling the technology to meet the demands of the cellular immunotherapy sector. Her technical expertise continues to drive the platform’s capabilities and market relevance.

With strong experience in Quality Management Systems, Neelima has ensured regulatory compliance, improved product quality, and optimised operational processes in both academic and industry settings at leading institutions, such as Harvard Medical School and Rubius Therapeutics. She has led initiatives to streamline operations while maintaining rigorous standards, vital for developing next-generation therapies. Beyond Avigen's platform, Neelima is experienced in developing 3D co-culture models for tumour microenvironment studies, drug sensitivity assays, pancreatic cancer research, as well as developing microfluidic technologies to capture circulating tumour cells.